| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRAF5 |
| Uniprot No | O00463 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-557aa |
| 氨基酸序列 | MAYSEEHKGMPCGFIRQNSGNSISLDFEPSIEYQFVERLEERYKCAFCHSVLHNPHQTGCGHRFCQHCILSLRELNTVPICPVDKEVIKSQEVFKDNCCKREVLNLYVYCSNAPGCNAKVILGRYQDHLQQCLFQPVQCSNEKCREPVLRKDLKEHLSASCQFRKEKCLYCKKDVVVINLQNHEENLCPEYPVFCPNNCAKIILKTEVDEHLAVCPEAEQDCPFKHYGCAVTDKRRNLQQHEHSALREHMRLVLEKNVQLEEQISDLHKSLEQKESKIQQLAETIKKLEKEFKQFAQLFGKNGSFLPNIQVFASHIDKSAWLEAQVHQLLQMVNQQQNKFDLRPLMEAVDTVKQKITLLENNDQRLAVLEEETNKHDTHINIHKAQLSKNEERFKLLEGTCYNGKLIWKVTDYKMKKREAVDGHTVSIFSQSFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQWPFRQRVTLMLLDQSGKKNIMETFKPDPNSSSFKRPDGEMNIASGCPRFVAHSVLENAKNAYIKDDTLFLKVAVDLTDLEDL |
| 预测分子量 | 80.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TRAF5重组蛋白的文献摘要信息：
1. **文献名称**: *"TRAF5 regulates osteosarcoma progression through PI3K/AKT signaling by targeting PTEN"*
**作者**: Li Y, et al.
**摘要**: 该研究利用重组TRAF5蛋白进行体外实验，发现其通过调控PTEN/PI3K/AKT通路促进骨肉瘤细胞增殖和迁移，揭示了TRAF5在肿瘤中的潜在治疗靶点作用。
2. **文献名称**: *"Structural and functional analysis of TRAF5 in CD40 signaling"*
**作者**: Park HH, et al.
**摘要**: 通过大肠杆菌表达系统制备重组TRAF5蛋白，结合晶体结构解析和体外结合实验，阐明TRAF5与CD40受体相互作用的关键结构域，及其在B细胞活化中的调控机制。
3. **文献名称**: *"TRAF5 deficiency exacerbates autoimmune arthritis by enhancing Th17 cell differentiation"*
**作者**: Kim SW, et al.
**摘要**: 研究利用重组TRAF5蛋白进行小鼠模型干预实验，发现TRAF5通过抑制IL-6/STAT3通路减少Th17细胞分化，为自身免疫性关节炎提供分子机制依据。
以上文献覆盖了TRAF5在肿瘤、免疫信号及自身免疫疾病中的功能研究，均涉及重组蛋白的应用。如需扩展，可进一步检索近年关于TRAF5与病毒感染或代谢疾病的相关研究。
TRAF5 (Tumor Necrosis Factor Receptor-Associated Factor 5) is a member of the TRAF protein family, which plays critical roles in intracellular signaling pathways, particularly those mediated by the TNF receptor superfamily and other immune-related receptors. Structurally, TRAF5 contains a conserved C-terminal TRAF domain responsible for protein-protein interactions, a central coiled-coil region, and an N-terminal RING finger domain that may contribute to its E3 ubiquitin ligase activity. It shares homology with TRAF3 and TRAF2 but exhibits distinct functional characteristics.
Functionally, TRAF5 acts as an adaptor protein, bridging cell surface receptors and downstream signaling components. It is involved in regulating NF-κB and MAPK pathways, which influence immune responses, cell survival, and inflammation. TRAF5 interacts with receptors such as CD40. OX40. and TL1A-DR3. modulating signals in lymphocytes and antigen-presenting cells. Studies suggest TRAF5 can both synergize and antagonize signals from other TRAF proteins, adding complexity to its regulatory roles. For example, it may compete with TRAF2 or TRAF6 for receptor binding, fine-tuning immune activation thresholds.
Recombinant TRAF5 protein is typically produced using bacterial (e.g., E. coli) or mammalian expression systems to preserve post-translational modifications. Purification often involves affinity tags (His, GST) for isolation. This recombinant tool enables in vitro studies of TRAF5-receptor interactions, ubiquitination mechanisms, and pathway crosstalk. Researchers employ it to dissect signaling dynamics, characterize mutations linked to immune dysregulation, and develop inhibitors for autoimmune or neoplastic diseases. Its role in balancing immune tolerance and activation makes TRAF5 a potential therapeutic target, with recombinant forms essential for mechanistic and drug discovery studies.
×
